Zurn files supplemental proxy disclosures for Elkay merger amid shareholder lawsuits

Zurn Elkay Water Solutions Corp

Three complaints filed in NY and PA federal courts allege proxy statement deficiencies; company denies merit.
Supplement adds Evercore selected-company valuation tables for Elkay and Zurn, including TEV/EBITDA multiples.
Supplement includes detailed Evercore DCF assumptions: discount rates 9.0-10.0% for Elkay, 8.5-9.5% for Zurn.
Equity research analyst price targets for Zurn ranged $38-$43 per share as of Feb 1-2, 2022.
Company states supplemental disclosures are voluntary to avoid litigation delay and are not an admission.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.